About this document
2019 - Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies To OvercomeTherapeutic Resistance in Lung Cancer by Fernando Fernández García is a document available to read on EtoBox.
The document discusses novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. It provides historical context on EGFR inhibitors and resistance mechanisms. It then describes several third-generation inhibitors in development and highlights osimertinib as the only FDA-approved third-generation inhibitor so far.
- Author
- Fernando Fernández García
- Language
- EN